Quantinno Capital Management LP Purchases 16,224 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Quantinno Capital Management LP lifted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 78.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 36,930 shares of the medical research company's stock after purchasing an additional 16,224 shares during the period. Quantinno Capital Management LP owned 0.07% of Charles River Laboratories International worth $6,817,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of CRL. Pinnacle Bancorp Inc. lifted its stake in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after buying an additional 65 shares during the period. Cornerstone Investment Partners LLC increased its position in Charles River Laboratories International by 3.7% in the 4th quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company's stock valued at $358,000 after buying an additional 69 shares in the last quarter. Metis Global Partners LLC grew its stake in Charles River Laboratories International by 4.4% in the fourth quarter. Metis Global Partners LLC now owns 1,720 shares of the medical research company's stock valued at $318,000 after acquiring an additional 72 shares during the period. Two Sigma Securities LLC lifted its holdings in shares of Charles River Laboratories International by 4.3% in the 4th quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company's stock worth $366,000 after purchasing an additional 81 shares in the last quarter. Finally, Wahed Invest LLC increased its stake in Charles River Laboratories International by 6.5% during the 4th quarter. Wahed Invest LLC now owns 1,321 shares of the medical research company's stock valued at $244,000 after purchasing an additional 81 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the sale, the executive vice president now directly owns 19,513 shares in the company, valued at approximately $2,837,385.33. This trade represents a 2.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Birgit Girshick bought 1,514 shares of the company's stock in a transaction dated Thursday, February 20th. The stock was purchased at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the purchase, the chief operating officer now owns 55,058 shares of the company's stock, valued at approximately $9,064,198.54. This represents a 2.83% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 5,040 shares of company stock valued at $807,407 in the last ninety days. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Trading Up 1.5%

CRL stock traded up $2.11 on Tuesday, reaching $143.49. The company's stock had a trading volume of 956,394 shares, compared to its average volume of 983,911. The firm has a market cap of $7.05 billion, a PE ratio of 956.60, a PEG ratio of 4.54 and a beta of 1.50. The business has a fifty day simple moving average of $134.84 and a two-hundred day simple moving average of $164.49. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $254.15. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. The firm had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company's revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.27 EPS. As a group, research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. TD Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price target for the company in a report on Wednesday, May 14th. Citigroup raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and upped their target price for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. JPMorgan Chase & Co. decreased their target price on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a research report on Thursday, February 20th. Evercore ISI upgraded shares of Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price objective for the company in a report on Thursday, May 8th. Finally, Morgan Stanley lowered their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $172.31.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).